Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mavacamten 15 mg Capsule Formulations
NCT05719805Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started Feb 2023; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05719805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719805.